NO20051681L - Lysaldring av hud og aktinskadebehandling - Google Patents

Lysaldring av hud og aktinskadebehandling

Info

Publication number
NO20051681L
NO20051681L NO20051681A NO20051681A NO20051681L NO 20051681 L NO20051681 L NO 20051681L NO 20051681 A NO20051681 A NO 20051681A NO 20051681 A NO20051681 A NO 20051681A NO 20051681 L NO20051681 L NO 20051681L
Authority
NO
Norway
Prior art keywords
actin
skin
light aging
damage treatment
damage
Prior art date
Application number
NO20051681A
Other languages
English (en)
Inventor
Alan James Husband
Graham Edmund Kelly
Cath Walker
Original Assignee
Novogen Res Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2002951572A external-priority patent/AU2002951572A0/en
Priority claimed from AU2003900236A external-priority patent/AU2003900236A0/en
Application filed by Novogen Res Pty Ltd filed Critical Novogen Res Pty Ltd
Publication of NO20051681L publication Critical patent/NO20051681L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Pyrane Compounds (AREA)

Abstract

Anvendelse av ekvol, dehydroekvol og andre isoflav-3-en blir beskrevet til å forhindre og/eller behandle hudlysaldring og aktinskade.Fremgangsmåter til å behandle disse tilstander er også beskrevet.
NO20051681A 2002-09-23 2005-04-05 Lysaldring av hud og aktinskadebehandling NO20051681L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2002951572A AU2002951572A0 (en) 2002-09-23 2002-09-23 Repair of uv-induced damage in skin
AU2003900236A AU2003900236A0 (en) 2003-01-21 2003-01-21 Repair of uv-induced damage in skin
PCT/AU2003/001265 WO2004026274A1 (en) 2002-09-23 2003-09-23 Skin photoageing and actinic damage treatment

Publications (1)

Publication Number Publication Date
NO20051681L true NO20051681L (no) 2005-04-05

Family

ID=32031299

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051681A NO20051681L (no) 2002-09-23 2005-04-05 Lysaldring av hud og aktinskadebehandling

Country Status (9)

Country Link
US (1) US20060153782A1 (no)
EP (1) EP1542654A4 (no)
JP (1) JP2006508058A (no)
CA (1) CA2499602A1 (no)
CZ (1) CZ2005181A3 (no)
MX (1) MXPA05003202A (no)
NO (1) NO20051681L (no)
NZ (1) NZ539149A (no)
WO (1) WO2004026274A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101965974A (zh) 2002-07-24 2011-02-09 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2003286781B2 (en) 2002-10-29 2009-05-21 Brigham Young University Use of equol for treating androgen mediated diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
AU2005239984B2 (en) * 2002-10-29 2010-06-03 Brigham Young University Use of equol for treating skin diseases
US7993629B2 (en) * 2008-12-23 2011-08-09 Avon Products, Inc. Topical compositions containing CIS-6-nonenol and its derivatives and methods for treating skin
MX368365B (es) 2009-12-22 2019-09-30 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
DK3781561T3 (da) 2018-04-18 2024-06-17 Constellation Pharmaceuticals Inc Modulatorer af methylmodificerende enzymer, sammensætninger og anvendelser deraf
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039733A1 (en) * 1996-04-23 1997-10-30 The Procter & Gamble Company Methods of regulating skin appearance with vitamin b3 compound
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
WO1998034591A1 (en) * 1997-02-11 1998-08-13 The Procter & Gamble Company Skin lightening compositions
TWI234467B (en) * 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
AUPP112497A0 (en) * 1997-12-24 1998-01-22 Novogen Research Pty Ltd Compositions and method for protecting skin from UV induced immunosupression and skin damage
AU3002299A (en) * 1998-03-16 1999-10-11 Procter & Gamble Company, The Methods for regulating skin appearance
CN1188107C (zh) * 1998-03-16 2005-02-09 宝洁公司 调节皮肤外观的组合物
EP1041964A4 (en) * 1998-09-10 2003-09-03 Avon Prod Inc METHOD AND COMPOSITIONS FOR REDUCING DERMATOLOGICAL AGING AND FOR REDUCING CRUSHING
AUPP868599A0 (en) * 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
US6638543B2 (en) * 2001-02-27 2003-10-28 Regents Of The University Of Michigan Use of natural EGFR inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth factor receptor
AUPR363301A0 (en) * 2001-03-08 2001-04-05 Novogen Research Pty Ltd Dimeric isoflavones
DE10121375B4 (de) * 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) * 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
FR2825277B1 (fr) * 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
EP1503751A4 (en) * 2002-04-09 2007-08-01 Novogen Res Pty Ltd THERAPEUTIC PROCESSES AND COMPOSITIONS WITH ISOFLAV-3-EN AND ISOFLAVAN STRUCTURES
CN101965974A (zh) * 2002-07-24 2011-02-09 儿童医院医疗中心 含有对映体牛尿酚的组合物和产物及其用途
AU2002951271A0 (en) * 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage

Also Published As

Publication number Publication date
EP1542654A1 (en) 2005-06-22
MXPA05003202A (es) 2005-07-05
NZ539149A (en) 2007-05-31
CA2499602A1 (en) 2004-04-01
EP1542654A4 (en) 2008-12-17
US20060153782A1 (en) 2006-07-13
JP2006508058A (ja) 2006-03-09
WO2004026274A1 (en) 2004-04-01
CZ2005181A3 (cs) 2005-08-17

Similar Documents

Publication Publication Date Title
NO20051681L (no) Lysaldring av hud og aktinskadebehandling
ATE415974T1 (de) Immunmodulatorische verbindungen sowie deren verwendungsverfahren
NO20052928L (no) Nye kjemiske forbindelser
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
NO20021830D0 (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
NO20041598L (no) Fremgangsmater for behandling eller profylakse av vaskulaer betennelse ved anvendelse av sterolabsorpsjonsinhibitor(er)
NO20044658L (no) Anvendelse av osteoprotegerin til behandling og/eller forhindring av fibrotiske sykdommer
ATE430572T1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
RU2008125106A (ru) Композиция для обработки волос, содержащая акриловый адгезив, чувствительный к давлению
NO20035231D0 (no) Peptider som kan nyttes for behandling av tumorer og andre tilstander som krever fjerning eller destruksjon av celler
DE60231050D1 (de) Verwendung von Totarol zur Behandlung von Pruritus
NO20054670D0 (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
ATE402699T1 (de) Verwendung von substituierten pyrazolen zur behandlung von allergien
WO2007123859A3 (en) Method and device to inactivate and kill cells and organisms that are undesirable
NO20075695L (no) Fremgangsmate til a behandle eller forhindre type-2 diabetes
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE410235T1 (de) Behandlung von ballastwasser
HK1087328A1 (en) Therapeutic composition for autoimmune conditions
TR28228A (tr) Deri gönlerinin islak muamelesi.
EA200401032A1 (ru) Антиинфарктные молекулы
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application